Clinical trial
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell…
NCT00129844 · Pharmacyclics LLC., Industry · Completed
Key facts
| NCT number | NCT00129844 |
|---|---|
| Title | Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer |
| Official title | Randomized Phase II Trial of Single Agent Motexafin Gadolinium for Second Line Treatment of Non-Small-Cell Lung Cancer |
| Lead sponsor | Pharmacyclics LLC., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma, Non-Small-Cell Lung Carcinoma, Lung Neoplasms |
| Intervention type | Drug |
| Interventions | Motexafin Gadolinium |
| Enrollment | 108 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Aug 12, 2005 |
| Last update posted | Aug 20, 2008 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: